FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Novartis.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Pediatric
- Sub-indication
- Ild
Related signal: Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment